Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 176

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 8
Chunk 176
---
 stock. As of June 30, 2025, we had 1,531,142 shares of common stock available for future issuance under the 2013 ESPP.Stock-based compensation expenseStock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:Three Months EndedJune 30,Six Months EndedJune 30,(In thousands)2025202420252024Stock options$4,622 $4,361 $9,022 $8,432 Restricted stock units7,507 6,211 14,191 11,177 Performance-based stock units2,188 750 2,188 750 Employee stock purchase plan375 243 650 440 Total stock-based compensation expense$14,692 $11,565 $26,051 $20,799 Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:Three Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Research and development expense$5,336 $4,460 $9,940 $8,235 Selling, general and administrative expense9,356 7,105 16,111 12,564 Total stock-based compensation expense$14,692 $11,565 $26,051 $20,799 

10. Loss per Share

Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net income (loss) per share calculation, stock options, RSUs and PSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs with performance and market vesting conditions, respectively, that were not deemed probable as of June 30, 2025 are not considered to be common stock equivalents.

14

We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is net loss from continuing operations. The control number concept requires that the same number of